Introduction {#Sec1}
============

Assessment of BRCA1/2 gene mutation status from formalin-fixed paraffin-embedded (FFPE) tissue became a routine procedure for patients with high-grade serous ovarian cancer, as patients with evidence of such mutations are eligible for therapies including the PARP inhibitor olaparib (Hennessy et al. [@CR7]; Mafficini et al. [@CR12]; Moschetta et al. [@CR15]; Muggia [@CR16]; Oza et al. [@CR18]). The role of BRCA1/2 gene mutations in patients with breast cancer is also getting more attention, with genetic counseling in view of a hereditary disease becoming a highly demanding field in patient care (Farrugia et al. [@CR4]; Gonzalez-Angulo et al. [@CR5]; Gross et al. [@CR6]; Kwon et al. [@CR8], [@CR9]). The majority of *BRCA1* mutated breast cancers are so-called "triple negative" or of "basal-type". In contrast, not all "triple negative" breast cancer patients have a germline *BRCA1*/*2* mutation. The indication for BRCA1/2 mutation testing is mainly based on clinical criteria, other than on histomorphological features (Dabbs [@CR2]; Lakhani et al. [@CR10]; Lips et al. [@CR11]).

The medullary phenotype of breast cancer, which is often but not exclusively encountered in *BRCA1* germline mutation carriers, cannot reliably be used as an indication for genetic testing. (Dabbs [@CR2]; Lakhani et al. [@CR10]; Lips et al. [@CR11]). The current WHO classification on breast cancer defines medullary differentiation as invasive high-grade carcinomas exhibiting various amounts of lymphocytic infiltration typically lacking in situ components and showing sharply demarcated edges towards the tumor periphery (Dabbs [@CR2]; Lakhani et al. [@CR10]; Lips et al. [@CR11]). Overall survival of typical and atypical medullary breast carcinomas seem to be quite similar to each other, however, prognostic difference to ductal non-special type (NST) breast cancer is controversially reported in the literature (Dabbs [@CR2]; Lakhani et al. [@CR10]; Lips et al. [@CR11]) (Mateo et al. [@CR13]; Mavaddat et al. [@CR14]). In case of *BRCA2* mutations in breast cancer, suggestive morphological and prognostic features are even more unspecific and thus less helpful. A wide range of histological subtypes, mainly a luminal hormone receptor positive phenotype, can be seen in breast cancer patients with *BRCA2* germline mutation (Dabbs [@CR2]; Lakhani et al. [@CR10]; Lips et al. [@CR11]).

In this study, we explored the relationship between a medullary phenotype in a series of breast cancer patients without known positive family history and *BRCA1*/*2* mutation status with next-generation sequencing (NGS) technology. We analyzed *BRCA1*/*2* mutation status in 32 breast cancer patients with medullary features (Fig. [1](#Fig1){ref-type="fig"}). The thus found pathogenic mutations were retrospectively compared with non-tumorous tissue and/or available long-term follow-up data.

Fig. 1Flow chart of study design

Materials and methods {#Sec2}
=====================

Breast cancer patients {#Sec3}
----------------------

All tissue samples were retrospectively retrieved from the archives of the Department of Pathology and Molecular Pathology, University Hospital Zurich, Switzerland, encompassing a period of 1994--2015. We identified 32 breast cancer cases displaying medullary histological features as defined in the WHO 2012 as follows: all tumors had some or all of the following features as sharp circumscription or pushing peripheral areas, syncytial growth pattern, mainly high-grade nuclear morphology and at least focal prominent stromal and intratumoral lymphocytic infiltration (Figs. [2](#Fig2){ref-type="fig"}, [3](#Fig3){ref-type="fig"}). Patients' age varied from 31 to 85 years (mean age 52.3 years). Tumor size varied from 1.2 to 6.5 cm (mean tumor size 2.44 cm). 16 of 32 cases (50%) were negative for estrogen and progesterone receptors and also for Her2 (triple negative intrinsic phenotype), 3 of 32 cases (9.3%) were Her2 positive and 13 of 32 cases (40.7%) were hormone receptor positive and Her2 negative. All patients underwent either mastectomy or local wide excision with axillary lymph node dissection (Table [1](#Tab1){ref-type="table"}). There was no history of ovarian cancer in this cohort, three patients had benign ovarian cysts including also one mature teratoma.

Fig. 2Histological appearance of breast carcinoma with medullary features. **a, b** Low-power view of an invasive breast cancer with medullary features showing abundant lymphocytic infiltration, serpentine-syntitial like tumor cell formation and sharp demarcation to tumor periphery, hematoxylin and eosin stain

Fig. 3**a, b** High-power view of an invasive breast cancer with medullary features. Syntitial tumor cell formation exhibiting high nuclear polymorphism and mitotic figures. Hematoxylin and eosin stain

Table 1Clinico-pathological features of the cohortCase numberHistological diagnosisAge (years)GradingTumor size (cm)ERPRHER2\
IHCHER2\
FISH1NST with medullary features39G32.4100% positive100% positiveScore 0Not amplified2NST with medullary features85G31.75% positive5% positiveNANot amplified3NST with medullary features57G31.9NegativeNegativeScore 0NA4NST with medullary features50G32.2NegativeNegativeScore 0NA5NST with medullary features52G31.2NegativeNegativeNANot amplified6NST with medullary features39G34NegativeNegativeNANot amplified7NST with medullary features31G32NegativeNegativeIHC 0NA8NST with medullary features53G31.2NegativeNegativeScore 3+Amplified9NST with medullary features69G32.6NegativeNegativeNANA10NST with medullary features59G32.6NegativeNegativeNANA11NST with medullary features49G31.2NegativeNegativeNANot amplified12NST with medullary features60G31.21% positive1% positiveNANot amplified13NST with medullary features49G32.65% positive5% positiveNANot amplified14NST with medullary features50G31NegativeNegativeNANot amplifed15NST with medullary features48G32,560% positive2% positveScore 1+Not amplified16NST with medullary features65G32.280% positiveNegativeScore 1+Not amplified17NST with medullary features49G30.9NegativeNegativeScore 0Not amplified18NST with medullary features36G34.5NegativeNegativeScore 0Not ampified19NST with medullary features56G32.3100% positive10% positiveScore 1+Not amplified20NST with medullary features43G32.2100% positive100% positiveScore 2+Not amplified21NST with medullary features45G33.5100% positive50% positiveScore 2+Not amplified22NST with medullary features44G36.5NegativeNegativeScore 1+Not amplified23NST with medullary features65G36100% positive90% positiveScore 1+Not amplified24NST with medullary features73G35100% positive80% positiveScore 2+Not amplified25NST with medullary features55G31.2NegativeNegativeScore 0NA26NST with medullary features36G3320% positive10% positiveScore 0Not amplified27NST with medullary features56G32.2100% positive20% positiveScore 1+Not amplified28NST with medullary features45G32.6100% positive80% positiveScore 3+Amplified29NST with medullary features54G31.2NegativenegativeScore 3+Amplified30NST with medullary features76G30.6NegativeNegativeScore 2+Not amplified31NST with medullary features47G32.2100% positiveNegativeScore 0Not amplified32NST with medullary features39G31.8NegativeNegativeScore 0Not amplified

The study is a part of a retrospective larger breast cancer study previously approved by the Ethical Committee of the Canton Zurich (KEK-ZH-2012-553). For selected cases, required by the ethical approval, informed consents were obtained. All cases enrolled into the study cohort were anonymized for the study.

Determination of hormone receptors and Her2 status {#Sec4}
--------------------------------------------------

The hormone receptors (estrogen, ER and progesterone, PR) were determined in all cases using routine antibodies and pretreatment conditions. HER2 status was determined using the DAKO Herceptest, the Ventana CB11 and Ventana 45A antibodies. Manual pretreatment protocols or semi-automatic and automatic benchmark systems have been used. Detailed technologies for ER/PR and HER2 status evaluation have been published, previously (Varga et al. [@CR22], [@CR23]).

Next-generation sequencing (NGS) {#Sec5}
--------------------------------

For all NGS assays, representative cancer areas for the microdissection and DNA isolation were selected and marked by Z.V. on a freshly cut hematoxylin-eosin (HE) section. The marked tumor area was punched (length 2--4 mm, diameter 0.6 mm) from the paraffin block and DNA was isolated using a Promega DNA purification kit (Promega, Wisconsin, USA). Isolated genomic DNA was quantified using a fluorometric assay (Qubit, Thermo Fisher Scientific, Massachusetts, USA) and NGS libraries were amplified with the AmpliSeq Library Kit 2.0 and the Oncomine BRCA Assay (Thermo Fisher Scientific). Clonal amplification und sequencing was performed with Hi-Q chemistry on the Ion PGM platform according to manufacturer's requirements (Thermo Fisher Scientific). NGS data was analyzed with the Torrent Suite v5.0.3 and the Ion Reporter v5.0 including the Oncomine BRCA workflow. NGS run metrics (on target reads, mean depth, uniformity) are summarized in Table [2](#Tab2){ref-type="table"}. NGS reads were aligned to the reference genome hg19/GRCh37 and the transcripts for BRCA1 (NM_007300.3) and BRCA2 (NM_000059.3). The detected variants were filtered to the coding exons and excluded if they were listed in the commonSNP database (minor allele frequency \> 1%). Additionally, variants were excluded if they had variant allele frequencies \< 4% and variant allele coverage \< 50× (internal validation of sensitivity of AmpliSeq assays). To further validate the performance of the Oncomine BRCA panel, a mixing dilution experiment was performed confirming the sensitivity of the assay for SNVs and INDELs. After filtering, the variants were annotated to the COSMIC, dbSNP, and ARUP BRCA databases (<http://arup.utah.edu/database/BRCA/>). ARUP classification was done according to Plon et al. ([@CR19]): (1) (not pathogenic or of no clinical significance); (2) (likely not pathogenic or of little clinical significance); (3) (uncertain); (4) (likely pathogenic); and (5) (definitely pathogenic). To further classify the impact of unknown mutations on protein level, SIFT (<http://sift.jcvi.org/>) and PolyPhen (<http://genetics.bwh.harvard.edu/pph/>) were used.

Table 2Next-generation sequencing (NGS) run metrics (on target reads, mean depth, uniformity)RV caseGeneTranskriptNucleotid changeAminoacid changeExonMutation ratioClinVar IDClinVar classARUP classdbSNPOn targetCoverageUniformity1--------------------97.96717594.112--------------------97.93324699.213--------------------97.05261198.034--------------------97.64294099.215--------------------98.1322699.216BRCA1NM_007300.3c.3700_3704del\
GTAAAp.Val1234fs110.8337542pathogenic5rs8035760997.42163799.197BRCA1NM_007300.3c.178C\>Tp.Gln60Ter50.5454349pathogenic5rs8035747197.74289299.218--------------------94.49113979.759--------------------98.49234798.710--------------------97.5162998.6611--------------------98.74412198.2812--------------------98.51183799.2113--------------------98.56196299.4814BRCA2NM_000059.3c.7469T\>C, c.7960C\>Gp.Ile2490Thr, p.Leu2654Val15, 170.98, 0.0496852,--1 likely benign; 1 uncertain significance,----rs11571707,--96.71168098.4715--------------------97.68199199.1816--------------------98.42232399.2117BRCA2NM_000059.3c.9976A\>Tp.Lys3326Ter270.5438266benign1rs1157183398.03184098.6918BRCA1NM_007300.3c.68_69delAGp.Glu23fs20.56--pathogenic5--98.14152199.219--------------------98.22176499.0920--------------------98.17152199.2121BRCA1NM_007300.3c.2584A\>Gp.Lys862Glu110.7737476benign1rs8035692798.39163399.4822BRCA2NM_000059.3c.4258G\>Tp.Asp1420Tyr110.3741549benign1rs2889772798.48219394.8823--------------------98.4221490.5824--------------------98.75193695.4725BRCA2NM_000059.3c.4258G\>Tp.Asp1420Tyr110.4541,549benign1rs2889772797.4234899.1426--------------------97.85217799.3527BRCA1NM_007300.3c.2521C\>Tp.Arg841Trp110.5317,681benign1rs180070992.7974391.7228--------------------97.69174199.0729--------------------98.36240099.230--------------------96.94193799.4731--------------------97.92167399.4132--------------------98.15129699.16

Results {#Sec6}
=======

Three of 32 cases (9%) had definitely pathogenic germline *BRCA1* mutations (ARUP class 5) which lead either to a frameshift or a STOP codon in the protein (Table [3](#Tab3){ref-type="table"}). No pathogenic somatic BRCA2 mutations were observed.

Table 3Pathogenicitiy classification of detected mutation in the analyzed 32 casesRV caseIIIIIIIVV1----------2----------3----------4----------5----------6--------BRCA1: p.Val1234fs7--------BRCA1: p.Gln60Ter8----------9----------10----------11----------12----------13----------14--BRCA2: p.Ile2490Thr--BRCA2: p.Leu2654Val--15----------16----------17BRCA2: p.Lys3326Ter--------18--------BRCA1: p.Glu23fs19----------20----------21BRCA1: p.Lys862Glu--------22BRCA2: p.Asp1420Tyr--------23----------24----------25BRCA2: p.Asp1420Tyr--------26----------27BRCA1: p.Arg841Trp--------28----------29----------30----------31----------32----------

The first patient (no. 6) was diagnosed with breast cancer at an age of 40 years. NGS-based *BRCA1*/*2* testing showed a 5-basepair deletion (c.3700_3704delGTAAA) in exon 11 in the *BRCA1* gene which lead to a frameshift at aminoacid position 1234 (p.Val1234fs). The mutation is registered in the databases ARUP, ClinVar (ID 37542) and dbSNP (rs80357609) to be pathogenic. A second independent NGS library was prepared and sequenced which successfully validated the *BRCA1* mutation p.Val1234fs. Retrospective follow-up search revealed a positive family history in this patient. Due to a contralateral breast cancer 20 years after the initial diagnosis, the patient underwent germline *BRCA1* mutation testing, revealing the same pathogenic mutation in *BRCA1*.

The second patient (no. 7) with a pathogenic *BRCA1* alteration had a nonsense mutation (c.178C\>T) in exon 5 in the *BRCA1* gene leading to a STOP codon in the protein (p.Gln60Ter). This mutation is as listed as well in the databases ARUP, ClinVar (ID 54349) and dbSNP (rs80357471) to be pathogenic. An independent NGS library was prepared and sequenced which successfully validated the mutation. Subsequent germline *BRCA1* mutation testing showed the same pathogenic mutation in *BRCA1*.

The third patient (no. 18) had as a deletion (c.68_69delAG) in the *BRCA1* gene, leading to a frameshift in the protein (p.Glu23fs). Subsequent NGS analysis of corresponding normal breast tissue revealed the same mutation, suggesting a hereditary disease. In this patient, there was no positive family history of breast cancer. Due to the young age (37 years at initial diagnosis) and the triple negative phenotype with medullary features, genetic counseling and testing was recommended to the patient at the weekly interdisciplinary tumor board. Four years after initial diagnosis, however, no records about germline *BRCA1*/*2* testing could be found.

Pathogenic mutations of the BRCA1 gene are illustrated in details in Fig. [4](#Fig4){ref-type="fig"}.

Fig. 4Pathogenic mutations of the BRCA1 gene in patients 6, 7 and 18

In six patients, benign, likely benign or mutations of unknown significance (VUS) were detected (ARUP class 1--3).

In one patient (no. 14), two SNVs were detected in exon 15 (p.Ile2490Thr) and 17 (p.Leu2654Val) of the *BRCA2* gene. The mutation in exon 15 showed an allele frequency of almost 100%, representing a homozygous SNP, which was further underlined by a dbSNP entry (rs11571707) with a minor allele frequency (MAF) of 1.9% in the human population. The same mutation is registered in ClinVar (ID 96852) with conflicting interpretation of clinical significance. However, these entries are benign (11 entries), likely benign (1 entry), and of uncertain significance (1 entry), suggesting a non-pathogenic impact. The second mutation in patient no. 14 was detected at low allele frequency of 4%. Since this is at the limit of detection of our NGS system, a second independent NGS library was prepared and sequenced. The mutation p.Leu2654Val was successfully verified with an allele frequency of 5%. Interestingly, this mutation is registered neither in COSMIC, dbSNP nor in the ARUP. The protein alteration prediction tools SIFT and PolyPhen revealed highly destabilizing (damaging) values of 0 and 0.87, respectively. Therefore, the exon 17 mutation in *BRCA2* (p.Leu2654Val) was classified as VUS.

One nonsense mutation (patient no. 17) was detected at the 3-prime end in exon 27 of the *BRCA2* gene, leading to a STOP codon (p.Lys3326Ter). This mutation is registered in the ARUP and the ClinVar database and was suggested to be clinically not significant (ARUP class 1) (Farrugia et al. [@CR4]; Tavtigian et al. [@CR21]), and benign (ClinVar ID 38266), respectively. Additionally, the mutation is listed in the dbSNP database (rs11571833) with a minor allele frequency (MAF) of 0.4% in the human population. The mutation was not validated in an independent NGS library run, since it was assumed to be non-pathogenic.

Additional mutations which were assumed to be non-pathogenic according to ClinVar and ARUP entries were detected in patient no. 21 (*BRCA1*, p.Lys862Glu), no. 22 (*BRCA2*, p.Asp1420Tyr), no. 25 (*BRCA2*, p.Asp1420Tyr), and no. 27 (*BRCA1*, p.Arg841Trp). These mutations were not validated with an independent NGS run due to non-pathogenicity either.

Discussion {#Sec7}
==========

We performed BRCA1/2 testing by next-generation sequencing in clinically sporadic breast cancer patients with medullary like breast cancer and without known *BRCA1* and *BRCA2* mutations at presentation. Our study demonstrates that about nine percent of medullary like breast cancer patients without any known positive family history were *BRCA1* gene mutation carriers, whereas no pathogenic somatic *BRCA1*/*2* mutations could be found.

*BRCA1*/*2* mutations regained clinical attention, as patients with high-grade serous ovarian carcinomas with pathogenic *BRCA1*/*2* mutations displayed improved overall and recurrence-free survival if treated with platinum-based therapy in combination with PARP inhibitors such as olaparib (Hennessy et al. [@CR7]; Mafficini et al. [@CR12]; Moschetta et al. [@CR15]; Muggia [@CR16]; Oza et al. [@CR18]; Kwon et al. [@CR9]; Muggia et al. [@CR17]). Patients with *BRCA1*/*2* germline mutated serous ovarian cancers responded better to first-line chemotherapy in the metastatic setting in comparison with sporadic serous high-grade carcinomas (Hennessy et al. [@CR7]; Mafficini et al. [@CR12]; Moschetta et al. [@CR15]; Muggia [@CR16]; Oza et al. [@CR18]; Kwon et al. [@CR9]; Muggia et al. [@CR17]). Furthermore, resistance to taxane containing regimens have been documented in serous high-grade ovarian carcinomas displaying *BRCA1*/*2* germline mutations (Hennessy et al. [@CR7]; Mafficini et al. [@CR12]; Moschetta et al. [@CR15]; Muggia [@CR16]; Oza et al. [@CR18]; Kwon et al. [@CR9]; Muggia et al. [@CR17]).

The role of pathogenic BRCA1/2 mutations in breast cancer is currently not linked to specific therapies and is rather restricted to the choice for genetic counseling (Chalasani and Livingston [@CR1]). The need for genetic counseling including germ line BRCA1/2 testing in breast cancer patients is increasing, however, selection criteria remain mostly a positive family history additionally to breast cancers harboring a triple negative intrinsic phenotype (Kwon et al. [@CR8], [@CR9]; Chalasani and Livingston [@CR1]). Specific histological signs only exist for germline mutations in *BRCA1*. Breast cancers arising in *BRCA1* germ line mutation carriers are mostly triple negative, of younger patients (\< 50 years), high-grade and display so-called medullary features. Medullary-type breast cancers are characterized by dense lymphocytic infiltrate and pushing peripheral borders (Gonzalez-Angulo et al. [@CR5]; Kwon et al. [@CR8], [@CR9]; Dabbs [@CR2]; Lakhani et al. [@CR10]; Chalasani and Livingston [@CR1]). The frequency of BRCA1 gene allelic loss were reported to be more frequent in ER negative than in ER positive sporadic breast cancer cases (39 vs 12%) (Rhiem et al. [@CR20]). In unselected triple negative breast cancers, around 19% mutations were reported in the BRCA1/2 genes including also scattered somatic mutations (15% in BRCA and 3.9% in BRCA2 genes) (Gonzalez-Angulo et al. [@CR5]). Interestingly, there is lack of data on sporadic medullary carcinomas and its association with BRCA1 germline or somatic mutations. The 6.25% frequency of BRCA1 frame shift mutations in our study is lower than reported frequencies in unselected triple negative breast cancers or in sporadic cases or in serous high-grade ovarian carcinomas without family history varying from 19 to 28%) (Gonzalez-Angulo et al. [@CR5]; Rhiem et al. [@CR20]) (Mafficini et al. [@CR12]; Moschetta et al. [@CR15]). Whether this lower frequency is due to the relatively small number of cases in our cohort or to the fact that medullary phenotype is alone not pathognomic enough to predict BRCA1 mutation status, needs to be validated in further studies. On the other hand, 40.7% of the cases were hormone receptor positive in our study, which is unusually high in comparison to classical triple negative phenotype of classical medullary breast carcinoma. The high proportion of hormone receptor positive cases might possibly reflect the histological variability of medullary differentiation in breast cancer and might also contribute to the low frequency of somatic BRCA1 mutations.

In selected triple negative breast cancer cases, 57% were found to have BRCA1 and 23% BRCA2 germ line mutations (Gonzalez-Angulo et al. [@CR5]).

The term BRCAness, defined as DNA repair loss in the BRCA1/2 genes without germ line mutations, resulting in the same function loss and inactivation the BRCA1/2 genes, has been conflictingly discussed and addressed in the literature (Muggia [@CR16]; Lips et al. [@CR11]; Muggia et al. [@CR17]; Chalasani and Livingston [@CR1]; Vollebergh et al. [@CR24]). Probably, the choice of technology for assessing the DNA damage as MPLA, qPCR, IHC or aCGH methodologies resulted in non-standardized definitions of what consists of BRCAness damage (Chalasani and Livingston [@CR1]; Lips et al. [@CR11]). In two studies, breast cancers with BRCA1-like signature, as defined as BRCAness of the BRCA1 gene were found in 18% of breast cancers and showing a better response to anthacyline-based or platin containing high-dose chemotherapies (Lips et al. [@CR11]; Vollebergh et al. [@CR24]). One further study reported a higher frequency of BRCA2-like signatures in hormone receptor positive breast cancer cases and also a better response to neoadjuvant chemotherapy with anthracycline-based regiments (Lips et al. [@CR11]). Which technology is the most reliable to predict clinical outcome or the indication to genetic counseling in cases with BRCAness evidence is not solved at the current time and needs clinical validation in further studies (Muggia [@CR16]; Muggia et al. [@CR17]; Chalasani and Livingston [@CR1]).

The current technology of next-generation sequencing in paraffin-embedded, formalin-fixed material was first described in ovarian high-grade serious cancer both for somatic and germ line mutations, providing a sensitivity of \> 90% after verifying the data with Sanger sequencing (Mafficini et al. [@CR12]). This technology became meanwhile standard in somatic BRCA1/2 testing in ovarian cancer and was also the choice of methodology in our study. The classification system for detected mutations using NGS and Sanger sequencing was recently defined by Eccles (Eccles et al. [@CR3]). A five-tier score system, ranging from non- or likely non-pathogenic mutations (classes 1/2) through uncertain significance as class 3 to likely or definitely pathogenic mutations (classes 4/5) is linked to recommendations in terms of clinical management and to assessing risk situation of the given patient (Eccles et al. [@CR3]). Scores 4/5 are recommended as high-risk patient with appropriate genetic counseling, whilst classes 1 and 2 should follow management based on family history alone. At the current time, no clear guidelines exist for the clinical management of genes of uncertain significance (class 3). (Farrugia et al. [@CR4]; Plon et al. [@CR19]; Tavtigian et al. [@CR21]) (Eccles et al. [@CR3]). In or study, we found three definitely pathogenic somatic mutations of the BRCA1 genes (class 5).

Based on the data in our cohort, medullary breast cancer phenotype without known family history in breast cancer, has a low frequency of somatic BRCA1 mutations, even though these mutations turned out to correlate with germ line mutations of the BRCA1 gene independently from other factors as younger age and triple negative intrinsic phenotype. These data might be of help in case genetic counseling in sporadic breast cancers with medullary features. On the other hand, medullary phenotype without family anamnesis did not have any class 4 or 5 somatic mutations in the BRCA2 gene, pointing out to the role of the BRCA1 gene only in breast cancer with medullary features. Our data need to be validated in further lager studies.
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